PE20130180A1 - Soluciones farmaceuticas orales que comprenden telbivudina - Google Patents

Soluciones farmaceuticas orales que comprenden telbivudina

Info

Publication number
PE20130180A1
PE20130180A1 PE2012002012A PE2012002012A PE20130180A1 PE 20130180 A1 PE20130180 A1 PE 20130180A1 PE 2012002012 A PE2012002012 A PE 2012002012A PE 2012002012 A PE2012002012 A PE 2012002012A PE 20130180 A1 PE20130180 A1 PE 20130180A1
Authority
PE
Peru
Prior art keywords
concentration
oral pharmaceutical
telbivudine
solutions including
pharmaceutical solutions
Prior art date
Application number
PE2012002012A
Other languages
English (en)
Inventor
Nabila Sekkat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38724394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130180(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20130180A1 publication Critical patent/PE20130180A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA SOLUCION ORAL QUE COMPRENDE: A) BETHA-L-TIMIDINA/2´-DESOXI-L-TIMIDINA (TELBIVUDINA) EN UNA CONCENTRACION DE 20-50 mg/ml; B) SACARINA DE SODIO EN UNA CONCENTRACION DE 0.2 mg/ml; C) UN AGENTE MEJORADOR/ENMASCARADOR TAL COMO SABOR DE FRUTA DE LA PASION EN UNA CONCENTRACION DE 1.0 mg/ml; D) UN SISTEMA CONSERVADOR TAL COMO ACIDO BENZOICO EN UNA CONCENTRACION DE 1.5 mg/ml; E) UN SISTEMA REGULADOR TAL COMO ACIDO DE CITRATO ANHIDRO EN UNA CONCENTRACION DE 9.6 mg/ml; DONDE LA SOLUCION ORAL SE REGULA A UN pH APROXIMADO DE 4 A 5. DICHA SOLUCION PRESENTA ESTABILIDAD Y CRECIMIENTO MICROBIANO RETARDADO
PE2012002012A 2007-07-12 2008-07-10 Soluciones farmaceuticas orales que comprenden telbivudina PE20130180A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07112381 2007-07-12

Publications (1)

Publication Number Publication Date
PE20130180A1 true PE20130180A1 (es) 2013-03-06

Family

ID=38724394

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012002012A PE20130180A1 (es) 2007-07-12 2008-07-10 Soluciones farmaceuticas orales que comprenden telbivudina
PE2008001158A PE20090476A1 (es) 2007-07-12 2008-07-10 Soluciones farmaceuticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2008001158A PE20090476A1 (es) 2007-07-12 2008-07-10 Soluciones farmaceuticas

Country Status (22)

Country Link
US (1) US8445457B2 (es)
EP (1) EP2178503A1 (es)
JP (1) JP5314014B2 (es)
KR (3) KR20120078754A (es)
CN (1) CN101686938B (es)
AR (1) AR067630A1 (es)
AU (1) AU2008274170B2 (es)
BR (1) BRPI0815562A2 (es)
CA (1) CA2693609A1 (es)
CL (1) CL2008002025A1 (es)
CO (1) CO6270204A2 (es)
EC (1) ECSP109871A (es)
IL (1) IL202961A (es)
MA (1) MA31507B1 (es)
MY (1) MY147366A (es)
NZ (1) NZ582443A (es)
PE (2) PE20130180A1 (es)
RU (1) RU2493826C2 (es)
TN (1) TN2010000008A1 (es)
TW (1) TW200911302A (es)
WO (1) WO2009007426A1 (es)
ZA (1) ZA200908993B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY173181A (en) 2011-05-13 2020-01-02 Array Biopharma Inc Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
US20140107130A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals, LLC Oral Solution Formulations of Aripiprazole
SI3154959T1 (sl) 2014-05-15 2019-10-30 Array Biopharma Inc 1-((3S,4R)-4-(3-fluorofenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4- metil-3-(2-metilpirimidin-5-il)-1-fenil-1H-pirazol-5-il)urea kot inhibitor TrkA kinaze
CN107708705A (zh) * 2015-04-26 2018-02-16 林承叡 改善肾脏病患者的肾脏功能和/或心脏功能的方法
CN107550866A (zh) * 2016-06-30 2018-01-09 康普药业股份有限公司 一种替比夫定制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
AU9186398A (en) 1997-09-26 1999-04-23 Wakamoto Pharmaceutical Co., Ltd. Aqueous preparation containing antiviral agent having purine or pyrimidine skeleton
DE19817264A1 (de) 1998-04-18 1999-10-21 Bayer Ag Neue Dihydropyrimidine
DE19817265A1 (de) 1998-04-18 1999-10-21 Bayer Ag Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe
PE20030545A1 (es) * 2001-10-31 2003-06-19 Schering Corp Formulaciones de jarabe de ribavirina
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
WO2006130217A2 (en) 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates

Also Published As

Publication number Publication date
JP2010533146A (ja) 2010-10-21
AU2008274170A1 (en) 2009-01-15
KR20100029829A (ko) 2010-03-17
CA2693609A1 (en) 2009-01-15
CL2008002025A1 (es) 2009-05-08
MY147366A (en) 2012-11-30
IL202961A (en) 2013-10-31
WO2009007426A1 (en) 2009-01-15
ECSP109871A (es) 2010-02-26
JP5314014B2 (ja) 2013-10-16
AR067630A1 (es) 2009-10-21
CN101686938A (zh) 2010-03-31
AU2008274170B2 (en) 2011-06-09
TW200911302A (en) 2009-03-16
BRPI0815562A2 (pt) 2015-02-18
US8445457B2 (en) 2013-05-21
MA31507B1 (fr) 2010-07-01
CO6270204A2 (es) 2011-04-20
US20100197629A1 (en) 2010-08-05
CN101686938B (zh) 2012-09-05
TN2010000008A1 (en) 2011-09-26
EP2178503A1 (en) 2010-04-28
PE20090476A1 (es) 2009-05-12
NZ582443A (en) 2011-04-29
RU2010104395A (ru) 2011-08-20
KR20120078754A (ko) 2012-07-10
KR20140019040A (ko) 2014-02-13
RU2493826C2 (ru) 2013-09-27
ZA200908993B (en) 2010-09-29

Similar Documents

Publication Publication Date Title
ES2531083T3 (es) Formulaciones estables de polipéptidos y usos de las mismas
PE20061094A1 (es) Formulacion liquida oral que comprende antigeno de rotavirus vivo atenuado
JP2010529999A5 (es)
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
DE602004026582D1 (de) Gepufferte dialyselösung
HK1156847A1 (en) Pharmaceutical formulations and methods for treating respiratory tract infections
PE20130180A1 (es) Soluciones farmaceuticas orales que comprenden telbivudina
ES2720954T3 (es) Formulaciones estabilizadas de estatina
AR052855A1 (es) Composiciones para el cuidado bucal que contienen un extrato de eucalyptus
RU2010139958A (ru) Стабилизированная фармацевтическая композиция, cодержащая доцетаксель
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
DK2151241T3 (da) Stabilt fast præparat, omfattende 4,5-epoxymorphinanderivat
ES2605495T3 (es) Solución de atomoxetina
NZ592647A (en) Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester
PE20080994A1 (es) Jarabes antihistaminicos, estables al almacenamiento sin azucar
CY1116465T1 (el) Φαρμακοτεχνικη μορφη για προφυλαξη ασθενειων της στοματικης κοιλoτητας
CY1112917T1 (el) Υγρες στοματικες συνθεσεις
UA102254C2 (ru) Жидкий состав для деферипрона с приятным вкусом
MA30554B1 (fr) Malates et formes polymorphes de l'acide ( 3s,5s)-7-[3-amino-5-methyl-piperidinyl ]-1-cyclopropyl-1,4-dihydro-8- methoxy-4-oxo-3-quinoleine-carboxylique
WO2011016049A3 (en) A stable composition of ready-to-use gemcitabine injection
ES2478447T3 (es) Formulaciones del ácido desoxicólico y sus sales
EA201270745A1 (ru) Улучшенный стабильный водный состав (e)-4-карбоксистирил-4-хлорбензилсульфона
AR080054A1 (es) Formulaciones antiparasitarias topicas
EA201070194A1 (ru) Стабильная жидкая фармацевтическая композиция на основе тразодона
PE20041063A1 (es) Composicion farmaceutica que comprende acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed